Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Oct 28, 2020

SELL
$15.7 - $20.84 $1,020 - $1,354
-65 Closed
0 $0
Q2 2020

Jul 20, 2020

BUY
$8.21 - $21.02 $16 - $42
2 Added 3.17%
65 $1,000
Q3 2019

Oct 15, 2019

BUY
$10.15 - $16.89 $639 - $1,064
63 New
63 $1,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Valeo Financial Advisors, LLC Portfolio

Follow Valeo Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valeo Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Valeo Financial Advisors, LLC with notifications on news.